Increased utilization of buprenorphine and methadone in 2018 compared to 2015 among Seattle-area persons who inject drugs

Abstract

ObjectiveTo describe utilization patterns of methadone and buprenorphine among persons who inject drugs (PWID) in the Seattle area in 2018, compared to 2015. MethodsData from the 2018 National HIV Behavioral Surveillance (NHBS) system were used to compare the proportions of PWID reporting treatment with buprenorphine or methadone to survey responses in 2015. Temporal trends were assessed by calculating adjusted prevalence ratios (aPR) using Poisson regression. ResultsThe sample included 498 PWID, of whom 39.2% (95% CI: 34.8–43.6%) reported past-year treatment with methadone and 21.9% (95% CI: 18.3–25.8%) reported buprenorphine. Participants in 2018 were significantly more likely to report past year receipt of buprenorphine (aPR = 4.43, 95% CI: 2.81–7.01) or methadone (aPR = 1.38, 95% CI: 1.02–1.87) compared to 2015. Most buprenorphine treated participants (67.6%) reported that they had received buprenorphine through low-barrier, community, or nonprofit programs. ConclusionsAmong PWID who use opioids in the Seattle area, methadone use increased 38%, and buprenorphine use more than quadrupled from 2015 to 2018. Approximately half of surveyed PWID who use opioids still reported no treatment with either medication, highlighting remaining treatment gaps.